...
search icon
vtgn-img

VistaGen Therapeutics Inc, Common Stock

VTGN

NAQ

$1.97

-$0.08

(-3.9%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$58.32M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
222.34K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.69
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.9 L
$4.21 H
$1.97

About VistaGen Therapeutics Inc, Common Stock

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline comprises of Fasedienol(PH94B), an investigational pherine nasal spray for the treatment of anxiety in adults with social anxiety disorder which is in Phase III clinical trial; and Itruvone(PH10), an odorless synthetic investigational neuroactive pherine nasal spray for the treatment of major depressive disorder which is in Phase II clinical trial. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders that is in Phase II clinical trial; PH15, an investigational pherine nasal spray with a novel for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders that is in Phase II clinical trial; and PH284, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatments of the loss of appetite associated with chronic disorders, such as cancer, heart disease, as well as cachexia that is in Phase II clinical trial. In addition, the company is developing an oral candidate, AV-101, an Oral NMDR glycine site antagonist for the treatment of depression and neurological disorders that is in phase I clinical trial. Further, its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVTGNSectorS&P500
1-Week Return-1.5%1.22%3%
1-Month Return-18.93%1.56%3.83%
3-Month Return-25.1%-7.42%8.24%
6-Month Return-23.35%-3.4%3.12%
1-Year Return-43.39%-7.99%11.97%
3-Year Return-93.16%3.5%57.3%
5-Year Return-87.73%36.42%101.7%
10-Year Return-99.56%81.06%199.52%

Financials

Mar '21Mar '22Mar '23Mar '24Mar '255YR TREND
Total Revenue1.09M1.11M(227.30K)1.06M486.00K[{"date":"2021-03-31","value":98.25,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-20.5,"profit":false},{"date":"2024-03-31","value":95.95,"profit":true},{"date":"2025-03-31","value":43.83,"profit":true}]
Cost of Revenue-815.20K509.80K568.00K-[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":62.54,"profit":true},{"date":"2024-03-31","value":69.68,"profit":true},{"date":"2025-03-31","value":"-","profit":true}]
Gross Profit1.09M1.11M(227.30K)1.06M486.00K[{"date":"2021-03-31","value":98.25,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-20.5,"profit":false},{"date":"2024-03-31","value":95.95,"profit":true},{"date":"2025-03-31","value":43.83,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":100,"profit":true},{"date":"2025-03-31","value":100,"profit":true}]
Operating Expenses19.02M48.89M59.04M34.09M56.46M[{"date":"2021-03-31","value":32.22,"profit":true},{"date":"2022-03-31","value":82.8,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":57.73,"profit":true},{"date":"2025-03-31","value":95.63,"profit":true}]
Operating Income(17.93M)(47.78M)(59.27M)(33.02M)(55.97M)[{"date":"2021-03-31","value":-1793380000,"profit":false},{"date":"2022-03-31","value":-4777890000,"profit":false},{"date":"2023-03-31","value":-5926800000,"profit":false},{"date":"2024-03-31","value":-3302100000,"profit":false},{"date":"2025-03-31","value":-5597300000,"profit":false}]
Total Non-Operating Income/Expense4.20K39.90K52.40K7.01M9.12M[{"date":"2021-03-31","value":0.05,"profit":true},{"date":"2022-03-31","value":0.44,"profit":true},{"date":"2023-03-31","value":0.57,"profit":true},{"date":"2024-03-31","value":76.92,"profit":true},{"date":"2025-03-31","value":100,"profit":true}]
Pre-Tax Income(17.93M)(47.76M)(59.24M)(29.36M)(51.41M)[{"date":"2021-03-31","value":-1793160000,"profit":false},{"date":"2022-03-31","value":-4775900000,"profit":false},{"date":"2023-03-31","value":-5924180000,"profit":false},{"date":"2024-03-31","value":-2935800000,"profit":false},{"date":"2025-03-31","value":-5141100000,"profit":false}]
Income Taxes2.60K3.40K5.90K4.00K7.00K[{"date":"2021-03-31","value":37.14,"profit":true},{"date":"2022-03-31","value":48.57,"profit":true},{"date":"2023-03-31","value":84.29,"profit":true},{"date":"2024-03-31","value":57.14,"profit":true},{"date":"2025-03-31","value":100,"profit":true}]
Income After Taxes(17.93M)(47.76M)(59.25M)(29.36M)(51.42M)[{"date":"2021-03-31","value":-1793420000,"profit":false},{"date":"2022-03-31","value":-4776240000,"profit":false},{"date":"2023-03-31","value":-5924770000,"profit":false},{"date":"2024-03-31","value":-2936200000,"profit":false},{"date":"2025-03-31","value":-5141800000,"profit":false}]
Income From Continuous Operations(17.93M)(47.76M)(59.25M)(29.36M)(51.42M)[{"date":"2021-03-31","value":-1793420000,"profit":false},{"date":"2022-03-31","value":-4776240000,"profit":false},{"date":"2023-03-31","value":-5924770000,"profit":false},{"date":"2024-03-31","value":-2936200000,"profit":false},{"date":"2025-03-31","value":-5141800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}]
Net Income(17.93M)(47.76M)(59.25M)(29.36M)(51.42M)[{"date":"2021-03-31","value":-1793420000,"profit":false},{"date":"2022-03-31","value":-4776240000,"profit":false},{"date":"2023-03-31","value":-5924770000,"profit":false},{"date":"2024-03-31","value":-2936200000,"profit":false},{"date":"2025-03-31","value":-5141800000,"profit":false}]
EPS (Diluted)(0.39)(0.25)(1.98)(2.07)(1.67)[{"date":"2021-03-31","value":-39,"profit":false},{"date":"2022-03-31","value":-25,"profit":false},{"date":"2023-03-31","value":-198,"profit":false},{"date":"2024-03-31","value":-207,"profit":false},{"date":"2025-03-31","value":-167,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VTGN
Cash Ratio 6.38
Current Ratio 6.51

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VTGN
ROA (LTM) -33.64%
ROE (LTM) -55.69%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VTGN
Debt Ratio Lower is generally better. Negative is bad. 0.17
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.83

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VTGN
Trailing PE NM
Forward PE NM
P/S (TTM) 118.19
P/B 0.82
Price/FCF NM
EV/R 8.05
EV/Ebitda NM
PEG NM

FAQs

What is VistaGen Therapeutics Inc share price today?

VistaGen Therapeutics Inc (VTGN) share price today is $1.97

Can Indians buy VistaGen Therapeutics Inc shares?

Yes, Indians can buy shares of VistaGen Therapeutics Inc (VTGN) on Vested. To buy VistaGen Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VTGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of VistaGen Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of VistaGen Therapeutics Inc (VTGN) via the Vested app. You can start investing in VistaGen Therapeutics Inc (VTGN) with a minimum investment of $1.

How to invest in VistaGen Therapeutics Inc shares from India?

You can invest in shares of VistaGen Therapeutics Inc (VTGN) via Vested in three simple steps:

  • Click on Sign Up or Invest in VTGN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in VistaGen Therapeutics Inc shares
What is VistaGen Therapeutics Inc 52-week high and low stock price?

The 52-week high price of VistaGen Therapeutics Inc (VTGN) is $4.21. The 52-week low price of VistaGen Therapeutics Inc (VTGN) is $1.9.

What is VistaGen Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of VistaGen Therapeutics Inc (VTGN) is 0.82

What is the Market Cap of VistaGen Therapeutics Inc?

The market capitalization of VistaGen Therapeutics Inc (VTGN) is $58.32M

What is VistaGen Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of VistaGen Therapeutics Inc is VTGN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top